Teladoc Health's shares have fallen 3.3% since its second-quarter 2026 earnings report, underperforming the S&P 500. The company reported an adjusted loss of 21 cents per share, beating the Zacks Consensus Estimate of a 24-cent loss, but revenue declined 4% year over year to $606.9 million, missing estimates. Strength in the Integrated Care segment and international revenues was offset by weakness in BetterHelp and declining access fees. For the full year, Teladoc lowered its revenue guidance to $2.362-$2.447 billion from a prior range of $2.481-$2.576 billion, while adjusted EBITDA guidance was narrowed to $271-$303 million. The stock carries a Zacks Rank #3 (Hold), with estimates trending downward.
Teladoc IncQ2 earnings beat but revenue missed and full-year guidance lowered
Medpace Holdings Inc